GILEAD SCIENCES, INC.
Company Stats
- Market Cap
- $184.8B
- as of Sep 30, 2026
- Shares Outstanding
- 1.2B
- Free Float
- 99.9%
Income Statement
- Revenue
- $29.4B
- Operating Income
- $10.0B
- Net Income
- $8.5B
- EBITDA
- $10.4B
- Non-cash Impairment
- $590.0M
- Revenue Growth, 3Y
- 2.6%
- FCF Margin, 3Y Avg
- 31.8%
- FCF Margin, Worst Year
- 27.4%
Cash Flow
- Free Cash Flow
- $9.5B
- FCF Yield
- 5.1%
- Owner FCF Yield
- 4.6%
Returns & Capital
- Dividends Paid
- $4.0B
- Dividend Yield
- 2.2%
- Dividend Payout, 3Y Avg
- 310.2%
- Share Repurchases
- $1.9B
- Buyback Yield, 3Y Avg
- 0.7%
- SBC, 3Y Avg
- $831.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $29.4B | $9.5B | 32.1% |
| FY2024 | $28.8B | $10.3B | 35.8% |
| FY2023 | $27.1B | $7.4B | 27.4% |
| FY2022 | $27.3B | $8.3B | 30.6% |
| FY2021 | $27.3B | $10.8B | 39.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 14, 2026
Theme Survey
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
October 14, 2026
Deals
Vir Biotechnology to License TCEs to Gilead for $135 Million
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Corcept Flags Direct Revenue Hit as IRA Pricing Rules Widen
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
October 14, 2026
Deals
Vir Biotechnology to License TCEs to Gilead for $135 Million
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Corcept Flags Direct Revenue Hit as IRA Pricing Rules Widen
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back